Procyon Advisors Trims Bristol Myers Squibb Stake

Institutional investor reduces position in biopharmaceutical company by nearly 57% in Q4

Mar. 24, 2026 at 9:38am

Got story updates? Submit your updates here. ›

Procyon Advisors LLC, an institutional investor, reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 56.8% during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 15,452 shares of the biopharmaceutical company's stock, valued at $833,000 at the end of the reporting period.

Why it matters

Institutional investors like Procyon Advisors play a significant role in the stock market, and changes to their holdings can provide insights into market sentiment and potential future performance of a company's stock.

The details

According to the 13F filing, Procyon Advisors sold 20,349 shares of Bristol Myers Squibb during the fourth quarter, reducing its total position in the company. The filing indicates that Procyon Advisors now owns 15,452 shares of the biopharmaceutical company's stock, worth approximately $833,000 at the end of the reporting period.

  • Procyon Advisors filed the 13F report for the fourth quarter of 2025.

The players

Procyon Advisors LLC

An institutional investor that manages investment portfolios.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Procyon Advisors' position in Bristol Myers Squibb could signal a shift in market sentiment or a strategic portfolio rebalancing by the institutional investor. However, further analysis of the broader market and the company's performance would be needed to draw any definitive conclusions.